FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509597238> ?p ?o ?g. }

• W2509597238 abstract "Abstract Background: Numerous studies from others and our institution have demonstrated that the presence of minimal residual disease (MRD), detected at the time of hematopoietic cell transplantation (HCT), is strongly and independently associated with increased relapse risk and short survival in adults with acute myeloid leukemia (AML) undergoing myeloablative allogeneic HCT in morphologic complete remission (CR). In contrast, very little information is available regarding the prognostic significance of peri-transplant MRD dynamics in these patients. Since bone marrow staging studies with multiparameter flow cytometric (MFC) assessment for MRD are routinely obtained not only before but also at approximately day +28 following transplantation at our institution, we here retrospectively studied the relationship between peri-HCT MRD dynamics and post-transplant outcomes in a large patient cohort. We asked whether persistence or disappearance of MRD might identify cohorts of patients in whom post-transplant therapy was particularly indicated or unnecessary. Patients and Methods: AML patients ³18 years of age were eligible for this retrospective analysis if they were in first or second morphologic CR or CR with incomplete blood count recovery (CRi) irrespective of the presence of MRD, underwent allogeneic HCT with myeloablative conditioning between 2006 and 2014, received peripheral blood or bone marrow as stem cell source, and had pre-HCT bone marrow staging studies available that included 10-color MFC assessments for MRD. MRD was identified as a cell population showing deviation from normal antigen expression patterns compared with normal or regenerating marrow; any level of residual disease was considered MRDpos. We considered post-HCT MRD assessments in patients in whom bone marrow re-staging with MFC MRD analysis were obtained 28±7 days after transplantation. For this analysis, the primary endpoint of interest was overall survival, which was estimated using the Kaplan-Meier method. Results: 311 patients were identified and included in this study. Consistent with our previous analyses, patients with MRD at the time of HCT (MRDpos; n=76) had significantly shorter survival than MRDneg patients (n=234; estimated 3 year post-HCT survival: 26% [95% confidence interval: 17-37%) vs. 73% [66-78%], P <0.001). 310 patients survived at least 21 days following transplantation; for 279 of these (89.7%), post-HCT MRD assessments were obtained at day +28±7 and available for analysis. 214 patients (76.7%) had no MFC evidence of MRD before and after HCT (MRDneg/MRDneg), 2 (0.7%) were MRDneg/MRDpos, 49 (17.6%) were MRDpos/MRDneg, and 14 (5.0%) were MRDpos/MRDpos. Of the 65 patients who had detectable MRD either before and/or after transplantation, 58 had decreasing levels of MRD (MRDdecr) over the peri-HCT period, whereas 7 patients had increasing MRD levels (MRDincr) around the time of transplantation. As depicted in Figure 1, MRDneg/MRDneg patients had excellent long-term outcomes (survival at 3 years after day +28 MRD assessment: 76% [69-82%]), whereas both MRDneg/MRDpos patients died within 70 days after the day +28 MRD assessment. Interestingly, for patients who were MRDpos before transplantation, outcomes were relatively poor regardless of whether or not they had persistent MRD around day +28 after transplantation (MRDpos/MRDneg patients: 23% [12-36%]; for MRDpos/MRDpos patients: 19% [4-44%]). However, long-term survival was only observed among MRDdecr patients (at 3 years after day +28 MRD assessment: 24% [14-37%]), whereas all MRDincr patients died a median of 97 (range: 15-808) days following the post-HCT MRD assessment (Figure 2). Conclusion: Patients who have no evidence of MRD before and after HCT have excellent long-term outcomes. In contrast, patients who are MRDpos before transplantation have poor survival expectations regardless of whether or not they clear MRD within the first 28 days after transplantation, but long-term survival is only found among some patients with decreasing MRD levels over the peri-transplant period. This finding suggests that patients who are MRDpos at the time of HCT should be considered for pre-emptive therapeutic strategies given their high risk of disease recurrence regardless of the day +28 MRD information. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures Radich: Incyte: Consultancy; Ariad: Consultancy; Gilliad: Consultancy; Novartis: Consultancy, Research Funding. Walter:Amphivena Therapeutics, Inc.: Consultancy, Research Funding; Seattle Genetics, Inc.: Research Funding; Covagen AG: Consultancy; AstraZeneca, Inc.: Consultancy; Pfizer, Inc.: Consultancy; Amgen, Inc.: Research Funding." @default.
• W2509597238 created "2016-09-16" @default.
• W2509597238 creator A5011104179 @default.
• W2509597238 creator A5013626352 @default.
• W2509597238 creator A5013754928 @default.
• W2509597238 creator A5016406533 @default.
• W2509597238 creator A5026823531 @default.
• W2509597238 creator A5028772063 @default.
• W2509597238 creator A5056405520 @default.
• W2509597238 creator A5057920623 @default.
• W2509597238 creator A5086909430 @default.
• W2509597238 creator A5089541690 @default.
• W2509597238 date "2015-12-03" @default.
• W2509597238 modified "2023-09-30" @default.
• W2509597238 title "Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation" @default.
• W2509597238 doi "https://doi.org/10.1182/blood.v126.23.173.173" @default.
• W2509597238 hasPublicationYear "2015" @default.
• W2509597238 type Work @default.
• W2509597238 sameAs 2509597238 @default.
• W2509597238 citedByCount "0" @default.
• W2509597238 crossrefType "journal-article" @default.
• W2509597238 hasAuthorship W2509597238A5011104179 @default.
• W2509597238 hasAuthorship W2509597238A5013626352 @default.
• W2509597238 hasAuthorship W2509597238A5013754928 @default.
• W2509597238 hasAuthorship W2509597238A5016406533 @default.
• W2509597238 hasAuthorship W2509597238A5026823531 @default.
• W2509597238 hasAuthorship W2509597238A5028772063 @default.
• W2509597238 hasAuthorship W2509597238A5056405520 @default.
• W2509597238 hasAuthorship W2509597238A5057920623 @default.
• W2509597238 hasAuthorship W2509597238A5086909430 @default.
• W2509597238 hasAuthorship W2509597238A5089541690 @default.
• W2509597238 hasConcept C126322002 @default.
• W2509597238 hasConcept C141071460 @default.
• W2509597238 hasConcept C143998085 @default.
• W2509597238 hasConcept C2777408962 @default.
• W2509597238 hasConcept C2778461978 @default.
• W2509597238 hasConcept C2778729363 @default.
• W2509597238 hasConcept C2779823535 @default.
• W2509597238 hasConcept C2780007613 @default.
• W2509597238 hasConcept C2908647359 @default.
• W2509597238 hasConcept C2911091166 @default.
• W2509597238 hasConcept C71924100 @default.
• W2509597238 hasConcept C99454951 @default.
• W2509597238 hasConceptScore W2509597238C126322002 @default.
• W2509597238 hasConceptScore W2509597238C141071460 @default.
• W2509597238 hasConceptScore W2509597238C143998085 @default.
• W2509597238 hasConceptScore W2509597238C2777408962 @default.
• W2509597238 hasConceptScore W2509597238C2778461978 @default.
• W2509597238 hasConceptScore W2509597238C2778729363 @default.
• W2509597238 hasConceptScore W2509597238C2779823535 @default.
• W2509597238 hasConceptScore W2509597238C2780007613 @default.
• W2509597238 hasConceptScore W2509597238C2908647359 @default.
• W2509597238 hasConceptScore W2509597238C2911091166 @default.
• W2509597238 hasConceptScore W2509597238C71924100 @default.
• W2509597238 hasConceptScore W2509597238C99454951 @default.
• W2509597238 hasLocation W25095972381 @default.
• W2509597238 hasOpenAccess W2509597238 @default.
• W2509597238 hasPrimaryLocation W25095972381 @default.
• W2509597238 hasRelatedWork W2283680236 @default.
• W2509597238 hasRelatedWork W2290759365 @default.
• W2509597238 hasRelatedWork W2415136340 @default.
• W2509597238 hasRelatedWork W2540389644 @default.
• W2509597238 hasRelatedWork W2556060579 @default.
• W2509597238 hasRelatedWork W2558618390 @default.
• W2509597238 hasRelatedWork W2561804775 @default.
• W2509597238 hasRelatedWork W2574313978 @default.
• W2509597238 hasRelatedWork W2578166772 @default.
• W2509597238 hasRelatedWork W2626219129 @default.
• W2509597238 hasRelatedWork W2768422444 @default.
• W2509597238 hasRelatedWork W2911646509 @default.
• W2509597238 hasRelatedWork W2913497327 @default.
• W2509597238 hasRelatedWork W2940899782 @default.
• W2509597238 hasRelatedWork W2980069641 @default.
• W2509597238 hasRelatedWork W2980759078 @default.
• W2509597238 hasRelatedWork W2981238963 @default.
• W2509597238 hasRelatedWork W2989047686 @default.
• W2509597238 hasRelatedWork W2992205326 @default.
• W2509597238 hasRelatedWork W3154150065 @default.
• W2509597238 isParatext "false" @default.
• W2509597238 isRetracted "false" @default.
• W2509597238 magId "2509597238" @default.
• W2509597238 workType "article" @default.